Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Extended cycle combined hormonal contraceptive Stories

Women Alter Menstrual Cycle
2013-05-10 09:24:13

April Flowers for redOrbit.com - Your Universe Online A new study led by researchers at the University of Oregon found that a surprising number of adult women ages 18 and up are opting to delay or completely skip their monthly menstruation. They are achieving this by deviating from the instructions that come with birth-control pills or other hormonal contraceptives. The study, published in the journal Contraception, found that most women who alter bleeding cycles do so for convenience...

Oral Contraceptives Ease Painful Periods: Study
2012-01-19 06:05:57

Results of a 30-year Scandinavian study show convincing evidence that use of combined oral contraceptive pills can help ease bloating, cramps and other painful menstrual symptoms. Previous studies and anecdotal evidence had suggested that the combined oral contraceptive pill could have an impact on painful periods.  However, a 2009 review of all the available research by the prestigious Cochrane Collaboration concluded that there was limited evidence for pain improvement. But the...

2011-12-07 15:57:00

PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy. Terms of the...

2011-11-10 15:00:00

PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit affirmed the district court's June 16, 2011 denial of Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction to prevent Watson from selling generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)). Watson launched Amethia(TM)...

2011-07-28 06:43:00

PARSIPPANY, N.J., July 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has launched Amethia(TM) (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)), the generic equivalent of Duramed Pharmaceuticals Inc.'s Seasonique(R). Watson began shipping the product today, following a denial by the United States Court of Appeals for the Federal Circuit of a request for a temporary...

2011-06-07 07:00:00

PARSIPPANY, N.J., June 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel® tablets. Watson expects to launch the product shortly. (Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )...

2011-03-25 16:59:00

MORRISTOWN, N.J., March 25, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that it has received a favorable decision from the U.S. Court of Appeals for the Federal Circuit related to its ongoing patent challenge in connection with Watson's Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of Teva Women's Health, Inc.'s SEASONIQUE®(...

2010-05-07 15:00:00

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product. On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the...

2010-01-08 07:30:00

MORRISTOWN, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.10 mg/0.02 mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by...

2009-11-16 07:22:00

NEWPORT, Ky., Nov. 16 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia. Lysteda was approved following a Priority...